Thirty blood clotting instances had been reported within the UK after the primary 18 million doses of the Oxford-AstraZeneca vaccine, the medicines regulator has stated.
The determine is 25 greater than beforehand reported.
The rely was up to date as a part of a rolling evaluate into Britain’s COVID vaccines, with the Medicines and Healthcare merchandise Regulatory Company stressing the advantages of the jab “far outweigh any identified unwanted side effects”.
Issues have been raised about blood clots after a tiny proportion of instances among the many tens of hundreds of thousands who’ve acquired the Oxford-AstraZeneca jab.
Some international locations, resembling Germany, have restricted its use to sure ages however the European medicines watchdog and the World Well being Organisation each say it is protected and efficient.
The MHRA stated on Thursday there had been “22 studies of cerebral venous sinus thrombosis (CVST) and eight studies of different thrombosis occasions with low platelets”.
The figures cowl 9 December 2020 to 21 March this yr, when 15.8 million doses of the AstraZeneca vaccine had been administered, and round 2.2 million second doses.
The regulator careworn that each one medicines have potential unwanted side effects and that the advantages of each COVID jabs means folks mustn’t hesitate to get vaccinated.
“The quantity and nature of suspected opposed reactions reported up to now aren’t uncommon compared to different sorts of routinely used vaccines,” stated the MHRA report.
Its stated the commonest unwanted side effects reported for each the Pfizer and Oxford-AstraZeneca vaccines had been “injection-site reactions” resembling a sore arm, and normal flu-like signs like headache, chills, aching, fatigue and nausea.
These are regular reactions to any vaccine because the physique produces an immune response are ought to disappear after a day or two, stated the MHRA.
It stated the unwanted side effects are reported extra ceaselessly in youthful folks.
Greater than 31 million folks within the UK have had a primary dose of one of many two vaccines, with second doses topping first doses in latest days as older folks get known as as much as full their therapy.
A 3rd accepted vaccine, from Moderna, can also be anticipated to be rolled out in April.
The vaccine rollout within the EU has been a lot slower and was hampered by some international locations pausing the Oxford-AstraZeneca jab till the European regulator gave it the inexperienced gentle and concluded it didn’t enhance the general variety of clots within the inhabitants.
Regardless of that, Germany stated this week that it wouldn’t give the vaccine to under-60s on the advice of its nationwide regulator.